Standard BioTools Inc (fra:FLB) Share Price

Company Profile

Business description
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Contact
50 Milk Street
10th Floor
BostonMA02109
USA
T: +1 650 266-6000
E: [email protected]
https://www.standardbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
389

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,782.82	28.44	-0.36%
DAX 40	25,181.65	190.10	-0.75%
Dow JONES (US)	52,352.84	515.14	-0.97%
FTSE 100	10,690.36	34.67	-0.32%
HKSE	23,093.37	158.69	0.69%
NASDAQ	26,048.44	39.58	0.15%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,647.09	16.34	-0.21%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%